Bcl-2 family proteins are highly conserved molecules that play a crucial role in regulating the release of apoptotic proteins from mitochondria. They possess Bcl-2 homology (BH) domains, which are ...
BUFFALO, NY- September 1, 2022 – A new research paper was published in Aging ("Aging (Albany NY)" by Medline/PubMed, "Aging-US" by Web of Science) on the cover of Volume 14, Issue 16, entitled, ...
ROCKVILLE, Md. and SUZHOU, China, July 10, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in ...
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic ...
A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure. This is an ASCO Meeting Abstract from the 2023 ASCO ...
A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows ...
China’s National Medical Products Administration approved Ascentage Pharma Group Corp. Ltd.’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) for treating adults with chronic lymphocytic ...
The therapy is already approved for certain patients with relapsed/refractory mantle cell lymphoma. Pirtobrutinib (Jaypirca) has received accelerated approval for use to treat patients with chronic ...
While Eli Lilly celebrated a “solid quarter” of earnings this morning, a look over the Big Pharma’s third-quarter presentation reveals that the company has quietly dumped two clinical-stage assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback